The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hong Jun | - |
dc.contributor.author | Lee, Suk-young | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.date.accessioned | 2021-09-03T23:54:30Z | - |
dc.date.available | 2021-09-03T23:54:30Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-05-09 | - |
dc.identifier.issn | 1664-042X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88665 | - |
dc.description.abstract | Gastric cancer and colorectal cancer are the leading cause of cancer mortality and have a dismal prognosis. The introduction of biological agents to treat these cancers has resulted in improved outcomes, and combination chemotherapy with targeted agents and conventional chemotherapeutic agents is regarded as standard therapy. Additional newly clarified mechanisms of oncogenesis and resistance to targeted agents require the development of new biologic agents. Aberrant activation of the inositide signaling pathway by a loss of function PTEN mutation or gain of function mutation/amplification of PIK3CA is an oncogenic mechanism in gastric cancer and colorectal cancer. Clinical trials with biologic agents that target the inositide signaling pathway are being performed to further improve treatment outcomes of patients with advanced gastric cancer and metastatic colorectal cancer (CRC). In this review we summarize the inositide signaling pathway, the targeted agents that inhibit abnormal activation of this signaling pathway and the clinical trials currently being performed in patients with advanced or metastatic gastric cancer and metastatic CRC using these targeted agents. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.title | The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.identifier.doi | 10.3389/fphys.2016.00168 | - |
dc.identifier.scopusid | 2-s2.0-84974623041 | - |
dc.identifier.wosid | 000443547100001 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN PHYSIOLOGY, v.7 | - |
dc.relation.isPartOf | FRONTIERS IN PHYSIOLOGY | - |
dc.citation.title | FRONTIERS IN PHYSIOLOGY | - |
dc.citation.volume | 7 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Physiology | - |
dc.relation.journalWebOfScienceCategory | Physiology | - |
dc.subject.keywordAuthor | phosphoinositide | - |
dc.subject.keywordAuthor | PI3K | - |
dc.subject.keywordAuthor | mTOR | - |
dc.subject.keywordAuthor | Akt | - |
dc.subject.keywordAuthor | colorectal cancer | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | targeted therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.